Gilead’s Tecartus dropped from a list of CAR-Ts with updated boxed warnings

Gilead’s Tecartus has been removed from the FDA’s list of CAR-T therapies that should have a boxed warning on the risks of secondary cancer after telling five other makers of the drug class to add the warning last week.

The agency wrote five safety communications dated…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks